Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92296 Châtenay-Malabry, France.
Adv Drug Deliv Rev. 2021 May;172:127-147. doi: 10.1016/j.addr.2021.02.018. Epub 2021 Mar 8.
Self-assembled cylindrical aggregates made of amphiphilic molecules emerged almost 40 years ago. Due to their length up to micrometers, those particles display original physico-chemical properties such as important flexibility and, for concentrated samples, a high viscoelasticity making them suitable for a wide range of industrial applications. However, a quarter of century was needed to successfully take advantage of those improvements towards therapeutic purposes. Since then, a wide diversity of biocompatible materials such as polymers, lipids or peptides, have been developed to design self-assembling elongated drug nanocarriers, suitable for therapeutic or diagnostic applications. More recently, the investigation of the main forces driving the unidirectional growth of these nanodevices allowed a translation toward the formation of pure nanodrugs to avoid the use of unnecessary side materials and the possible toxicity concerns associated.
近 40 年前，由两亲分子自组装而成的圆柱形聚集体出现。由于其长度可达数微米，这些粒子表现出独特的物理化学性质，如重要的柔韧性，以及在高浓度样品中的高粘弹性，使它们适用于广泛的工业应用。然而，成功地将这些改进应用于治疗目的需要四分之一个世纪的时间。从那时起，已经开发出了多种生物相容性材料，如聚合物、脂质或肽，以设计自组装的长形药物纳米载体，适用于治疗或诊断应用。最近，对驱动这些纳米器件单向生长的主要力的研究，使得能够向纯纳米药物的形成方向转化，以避免使用不必要的辅助材料和可能存在的毒性问题。
